Can we count your visit with Google Analytics? No ads, no profiles. Details
IBO
USHealth Care · Biotechnology
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Structural: microcap biopharma with four early-stage platforms spanning antivirals, antimicrobials, and consumer wellness - all pre-revenue or minimal revenue.
merger with Dr. Ashley's (July 2026 target) could inject commercial revenue and brand-name consumer distribution; 3F and Equivir platforms address persistent unmet need in broad-spectrum antimicrobials.
going-concern qualification, heavy cash burn, no meaningful product revenue, sub-$60M float with thin liquidity - execution and dilution risk are acute.
It reads our $IBO data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
High-signal only
No major news in the last 7 days for IBO - only listicles and opinion pieces, which we filter out by default. See everything anyway.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.